Cargando…
A170 ADVERSE EVENTS & SEROLOGICAL RESPONSES FOLLOWING SARS-COV-2 VACCINATION IN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE
BACKGROUND: The rapid development and distribution of SARS-CoV-2 vaccines has raised concerns surrounding vaccine safety in immunocompromised populations, such as those with inflammatory bowel disease (IBD). PURPOSE: We described adverse events (AEs) following SARS-CoV-2 vaccination in those with IB...
Autores principales: | Markovinovic, A, Herauf, M, Quan, J, Hracs, L, Windsor, J W, Sharifi, N, Coward, S, Caplan, L, Gorospe, J, Ma, C, Panaccione, R, Ingram, R, Kanji, J, Tipples, G, Holodinsky, J, Berstein, C, Mahoney, D, Bernatsky, S, Benchimol, E, Kaplan, G G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991202/ http://dx.doi.org/10.1093/jcag/gwac036.170 |
Ejemplares similares
-
Adverse Events and Serological Responses After SARS-CoV-2 Vaccination in Individuals With Inflammatory Bowel Disease
por: Markovinović, Ante, et al.
Publicado: (2023) -
Serological responses to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel disease
por: Quan, Joshua, et al.
Publicado: (2022) -
Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease
por: Quan, Joshua, et al.
Publicado: (2023) -
A195 DURABILITY OF SEROLOGICAL RESPONSES AFTER SECOND, THIRD AND FOURTH DOSE OF SARS-COV-2 VACCINATION IN INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE COHORT STUDY
por: Sharifi, N, et al.
Publicado: (2023) -
A193 DEMOGRAPHIC, SOCIAL AND OCCUPATIONAL FACTORS THAT PREVENTED EXPOSURE TO SARS-COV-2 IN INFLAMMATORY BOWEL DISEASE PATIENTS DURING THE COVID-19 PANDEMIC: A PROSPECTIVE COHORT STUDY
por: Caplan, L N, et al.
Publicado: (2023)